# TRimetazidine for acUte on Chronic Liver Failure STudy

> **NCT03737448** · PHASE1 · SUSPENDED · sponsor: **Martin Pharmaceuticals** · enrollment: 30 (estimated)

## Conditions studied

- Acute-On-Chronic Liver Failure

## Interventions

- **DRUG:** Trimetazidine

## Key facts

- **NCT ID:** NCT03737448
- **Lead sponsor:** Martin Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2018-11-28
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2021-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03737448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03737448, "TRimetazidine for acUte on Chronic Liver Failure STudy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03737448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*